Vestal Point Capital, LP: 13F holdings
CIK 19749152026Q2
| Positions | 68 |
|---|
| Reported value | $4.3bn |
|---|
| Filed | 2026-08-14 |
|---|
Change since last quarter
| Positions | 68 (-22 vs prior quarter) |
|---|
| Reported value | $4.3bn (+19.6%) |
|---|
Top 10 holdings
| Security | Shares | Value | Weight |
|---|
| BMRN BioMarin Pharmaceutical Inc | 6,025,000 | $344.8m | 8.1% |
| NBIX Neurocrine Biosciences Inc | 1,880,000 | $316.8m | 7.4% |
| ABVX Abivax SA | 2,349,443 | $313.1m | 7.3% |
| UTHR United Therapeutics Corp | 435,000 | $235.7m | 5.5% |
| ELVN Enliven Therapeutics Inc | 4,000,000 | $203.0m | 4.7% |
| NRIX Nurix Therapeutics Inc | 8,050,000 | $195.3m | 4.6% |
| BCAX Bicara Therapeutics Inc | 5,250,000 | $155.9m | 3.6% |
| TSHA Taysha Gene Therapies Inc | 19,415,000 | $132.2m | 3.1% |
| ARWR Arrowhead Pharmaceuticals Inc | 1,575,000 | $128.4m | 3.0% |
| ABT Abbott Laboratories | 1,400,000 | $127.0m | 3.0% |
Get the full book
import finzdata as yf
yf.Client().manager_holdings(cik="1974915")
Every position, quarter by quarter since 2013, with adds, trims and exits, on the look-back bundles.
Get a free API keySee history bundlesDownload free samples